Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Docetaxel and AZD4547 in Recurrent FGFR1-Amplified Squamous NSCLC
NCT01824901Phase 2Completed
- Sponsor
- ECOG-ACRIN Cancer Research Group
- Start
- Jan 2014
- Primary completion
- Jul 2014
- Countries
- 1
01
Overview
A Phase 2 trial of fexagratinib in squamous cell carcinoma of the lung (SCCL), sponsored by ECOG-ACRIN Cancer Research Group. Started Jan 2014; status: completed.
02
Drugs
fexagratinib
03
Conditions
squamous cell carcinoma of the lung (SCCL)
Beyond the preview
Go deeper on NCT01824901.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01824901.